The U.S. Food and Drug Administration in April 2011approved Rituxan (rituximab), in combination with glucocorticoids (steroids), to treat patients with Wegener’s granulomatosis (WG) and microscopic polyangiitis (MPA), two rare disorders that cause blood vessel inflammation (vasculitis). Case reports and sereis suggest that it may also be effective in otehr types of vasculitis, particularly those with antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis. Several patients with chronic cutaneous small-vessel vasculitis have also been treated effectively with this agent. Interestingly, one case report suggested that Rituxan itself can cause leukocytoclastic vasculitis.
For Proffessional verison see here
You can become a Site Sponsor. Or you may wish to support our work with a Donation.
Cancer Treatment Today
228 Park Ave S #70464
New York, NY 10003-1502
info@cancertreatmenttoday.org
Tel - 212-372-7263